However, reports suggesting an altered expression and activity of ERα and an altered PR A/B ratio in BRCA1/2 mutation carriers demand not only the clinical determination of these receptor protein subtypes in this BC subgroup, but also necessitate studies including larger BRCA1/2 case numbers addressing the effect of different HRT regimens on cancer risk in these patients. This evidence concerns the gene BRCA1 and breast cancer.